Triplet Chemotherapy Enters Phase 2 Testing in Relapsed or Refractory AML
A phase 2 study in relapsed and refractory acute myeloid leukemia will examine whether a three-drug regimen built around mitoxantrone hydrochloride liposome, cladribine, and sotoraclib can produce measurable remission activity in a population with few durable options. The protocol is single-center, single-arm, and open-label, with an estimated enrollment of 20 adults and adolescents aged 16 to 65 years. It is designed to ask a practical question in a difficult disease: can this combination induce early disease control quickly enough to justify further development?
The trial places overall response rate at the center of evaluation, measured at the end of cycle 1, a 28-day treatment block. Complete remission rate is also tracked at the end of cycle 1, with follow-up extending up to 6 months, while adverse events will be monitored from first dose through 30 days after the last study drug administration. Survival and relapse status will be followed beyond treatment, which gives the study a longer clinical lens than a single induction cycle alone. In a leukemia setting where early cytoreduction can define the next therapeutic step, those endpoints are not abstract metrics; they are the difference between proceeding to consolidation, transplant planning, or rapidly moving to a salvage alternative.
Why This Regimen Was Chosen for a High-Risk Population
The study population is constrained to patients with confirmed AML by WHO classification who have already relapsed or become refractory after at least one prior line of anti-leukemia therapy. Eligibility also requires ECOG performance status 0 to 2 and adequate organ function, including total bilirubin no more than 1.5 times the upper limit of normal, AST and ALT no more than 2.5 times the upper limit of normal, and creatinine clearance of at least 50 mL/min. Those limits reflect a familiar reality in hematologic oncology: combination chemotherapy can only be delivered safely when marrow reserve, liver handling, and renal clearance are sufficient to tolerate the pharmacologic load.
The regimen itself is structured as a single treatment cycle with sequential intensity. Mitoxantrone hydrochloride liposome is given at 20 mg/m² on day 1, cladribine at 5 mg/m² on days 1 through 5, and sotoraclib at 20 mg on day 1, 40 mg on day 2, 80 mg on day 3, and 160 mg on days 4 through 9. The dosing escalation for the final agent suggests a deliberate attempt to move from initiation to sustained target pressure within the same cycle. In relapsed AML, where resistant clones often persist after prior exposure to cytotoxic therapy, a regimen that couples DNA damage with another mechanistic axis may offer a better chance of erasing dominant subclones than any single drug alone.
The official title names sotorasib, while the study synopsis lists sotoraclib in the dosing schedule. The protocol text itself does not resolve that naming difference, so any interpretation has to stay inside the document as written.
Safety Filters Reflect the Fragility of the Target Population
Exclusion criteria remove several groups at heightened risk of treatment-related harm. Patients with acute promyelocytic leukemia are excluded, as are those who received an allogeneic hematopoietic stem cell transplant within 100 days before enrollment. Active uncontrolled severe infection blocks participation, as does clinically significant cardiovascular disease, including uncontrolled arrhythmia or myocardial infarction within 6 months. Central nervous system leukemia is excluded as well, along with pregnancy, breastfeeding, and any severe medical or psychiatric condition that could interfere with study participation.
These exclusions mirror the toxicities hematologists worry about most when layering intensive agents in an already compromised patient: infectious complications during neutropenia, cardiac strain from anthracycline-like exposure, and organ dysfunction that can magnify adverse effects before a patient has any chance to benefit. A patient with relapsed AML can deteriorate quickly, and a regimen that looks feasible on paper can become intolerable if baseline infection or cardiac disease is underappreciated. The protocol’s screening rules are designed to keep the early safety signal interpretable rather than muddied by predictable preventable harm.
What the Endpoints Can and Cannot Prove
With only 20 participants and no comparator arm, the study cannot establish superiority over other salvage approaches. It can, however, provide an early read on whether the triplet generates enough remission activity to justify a larger trial. In relapsed or refractory AML, even a modest response rate can matter if it opens a path to transplant, deeper molecular testing, or a meaningful remission interval; a weak signal, by contrast, would be enough to halt development before the regimen reaches broader use.
The trial’s open-label, single-group design also means response assessment will depend on direct clinical and laboratory evaluation rather than blinding. That is standard in many early oncology studies, but it places weight on clear response definitions and consistent marrow assessment at the end of cycle 1. Because the study follows relapse status and survival, later outcomes may reveal whether any initial remissions translate into durable disease control or merely transient cytoreduction.
A Small Phase 2 Cohort With High Clinical Stakes
This study is scheduled to begin in December 2026, with primary completion estimated for December 2028 and final completion in May 2029. It is sponsored by The Affiliated People’s Hospital of Ningbo University and carries ClinicalTrials.gov identifier NCT07874737. The record also states that no individual participant data sharing plan is in place.
For now, the most important feature of the protocol is its clinical austerity. It does not promise broad generalizability, and it does not pretend that a 20-patient phase 2 study can settle the treatment question in relapsed AML. What it can do is test whether a tightly assembled combination of mitoxantrone liposome, cladribine, and the protocol’s third agent produces enough early response to keep the strategy alive. In a disease defined by resistance, short response windows, and rapid clinical decline, that first-cycle readout will carry most of the weight.